Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
On May 15, 2025, Telomir Pharmaceuticals announced the identification of Telomir-Ag2, a novel drug candidate with successful preclinical validation of its antimicrobial activity. This stabilized Silver(II) complex demonstrated broad-spectrum antibacterial activity, including effectiveness against drug-resistant strains like MARSA, and showed greater activity than its predecessor, Telomir-Ag1. The development marks a significant advancement in antimicrobial science, potentially impacting treatment for drug-resistant infections in high-risk settings. Telomir plans to advance Telomir-Ag2 through formulation development and strategic evaluations.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of antimicrobial drugs. The company utilizes its proprietary Telomir-1 platform to create innovative drug candidates, with a market focus on addressing drug-resistant infections.
Average Trading Volume: 167,897
Technical Sentiment Signal: Sell
Current Market Cap: $81.85M
Find detailed analytics on TELO stock on TipRanks’ Stock Analysis page.